In this video, Elizabeth Plimack, MD, MS, FASCO, Deputy Director at Fox Chase Cancer Center, discusses current treatments for ...

Most generalized MG patients have ocular symptoms at presentation, which progress and cause generalized MG involving the ...

Every year on 4th February, the world celebrates World Cancer Day. This day is a global initiative aimed at raising awareness ...

February is National Cancer Prevention Month and to help people keep life flowing smoothly, the Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), is ...

Researchers at Imperial College London are launching a major study to investigate whether shopping behaviours shown in ...

Recommendation based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% ...

Following an extraordinary surge in its share price of more than 200% during January, ImmunityBio now faces the critical task of justifying its elevated market ...

Pending Health Canada and FDA regulatory approval, light-activated Ruvidar® represents a potentially transformative, bladder-sparing treatment option for patients with limited alternatives, addressing ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...

ImmunityBio is advancing its oncology development program beyond its core focus on bladder cancer. The biotechnology firm has initiated a new mid-stage clinical study investigating a chemotherapy-free ...